A Tutorial on Target-Mediated Drug Disposition (TMDD) Models

被引：113

作者：

Dua, P. ^{[1
]}

Hawkins, E. ^{[1
,2
]}

van der Graaf, P. H. ^{[3
]}

机构：

[1] Pfizer Neusentis, Pharmatherapeut Res Clin Pharmacol, Cambridge, England

[2] Univ Surrey, Dept Math, Guildford, Surrey, England

[3] LACDR, Syst Pharmacol, Leiden, Netherlands

来源：

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2015年 / 4卷 / 06期

关键词：

D O I：

10.1002/psp4.41

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Target-mediated drug disposition (TMDD) is the phenomenon in which a drug binds with high affinity to its pharmacological target site (such as a receptor) to such an extent that this affects its pharmacokinetic characteristics. (1) The aim of this Tutorial is to provide an introductory guide to the mathematical aspects of TMDD models for pharmaceutical researchers. Examples of Berkeley Madonna2 code for some models discussed in this Tutorial are provided in the Supplementary Materials.

引用

页码：324 / 337

页数：14

共 84 条

[1] Partial derivative - Based sensitivity analysis of models describing target-mediated drug disposition [J].

Abraham, Anson K. ;

Krzyzanski, Wojciech ;

Mager, Donald E. .

AAPS JOURNAL, 2007, 9 (02) :E181-E189

[2] Type I Interferon Receptor is a Primary Regulator of Target-Mediated Drug Disposition of Interferon-β in Mice [J].

Abraham, Anson K. ;

Kagan, Leonid ;

Kumar, Sarmishtha ;

Mager, Donald E. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (01) :327-332

[3] The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics [J].

Agoram, Balaji M. ;

Martin, Steven W. ;

van der Graaf, Piet H. .

DRUG DISCOVERY TODAY, 2007, 12 (23-24) :1018-1024

[4] Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics [J].

Agoram, Balaji M. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (02) :153-160

[5] Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in Rats [J].

Ait-Oudhia, Sihem ;

Scherrmann, Jean-Michel ;

Krzyzanski, Wojciech .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (03) :897-910

[6]

Aston P.J., 2013, J MATH BIOL

[7] Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: Predicting in vivo potency [J].

Aston, Philip J. ;

Derks, Gianne ;

Raji, Adewale ;

Agoram, Balaji M. ;

van der Graaf, Piet H. .

JOURNAL OF THEORETICAL BIOLOGY, 2011, 281 (01) :113-121

[8] The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis [J].

Betts, Alison M. ;

Clark, Tracey H. ;

Yang, Jianxin ;

Treadway, Judith L. ;

Li, Mei ;

Giovanelli, Michael A. ;

Abdiche, Yasmina ;

Stone, Donna M. ;

Paralkar, Vishwas M. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 333 (01) :2-13

[9]

Cao Y., 2014, J PHARMACOKINET PHAR

[10] Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody [J].

Abhijit Chakraborty ;

Stacey Tannenbaum ;

Christiane Rordorf ;

Philip J. Lowe ;

David Floch ;

Hermann Gram ;

Sandip Roy .

Clinical Pharmacokinetics, 2012, 51 (6) :e1-e18

← 1 2 3 4 5 6 7 8 9 →